Birch Bark Topical Formulation for Neurocutaneous Pain Relief

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current treatments are inadequate for mitigating conditions associated with neurocutaneous malcircuitry, which involves aberrant neural conduction and transmission leading to chronic pain, inflammation, and functional disruptions, as they often fail to effectively terminate extraneous neural transmissions and restore normal neural function.

Innovation Solution

A topical formulation derived from birch tree bark, specifically Betula alba, which stimulates lymphatic flow and clearance, disrupting cytokine-induced neural malcircuitry by removing accumulated neurotransmitters and cytokines, thereby terminating abnormal neural transmissions and conduction.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments are used for neurocutaneous malcircuitry, then treatment is provided, but extraneous neural transmissions are not effectively terminated and normal neural function is not restored

Engineering Contradiction:
Improveeffectiveness in terminating extraneous neural transmissionsVSAvoidrestoration of normal neural function
Core Design Contradiction:
ReliabilityVSProductivity

Solution Approach 1:

The patent extracts and removes accumulated neurotransmitters and cytokines from the neural circuitry through lymphatic stimulation, thereby eliminating the harmful substances that sustain extraneous neural transmissions and enable restoration of normal neural function

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The formulation acts as an intermediary substance that facilitates the removal of accumulated neurotransmitters and cytokines by stimulating lymphatic flow, thereby enabling termination of abnormal neural transmissions without directly blocking neural signals

Inventive Principle:
Principle #24Intermediary (Mediator)

2Object-affected harmful factors

If the formulation is applied to alleviate pain and inflammation, then symptom relief is achieved, but normal pain transmission may be blocked

Engineering Contradiction:
Improvepain and inflammationVSAvoidblocking of normal pain transmission
Core Design Contradiction:
Object-affected harmful factorsVSObject-generated harmful factors

Solution Approach 1:

The formulation provides localized action by stimulating lymphatic flow specifically in the applied area to remove accumulated neurotransmitters and cytokines, thereby relieving pain and inflammation only where needed without interfering with normal pain transmission pathways

Inventive Principle:
Principle #3Local quality

Solution Approach 2:

The formulation enables the body's own lymphatic system to clear accumulated harmful substances, thereby providing natural pain and inflammation relief without requiring external intervention that might block normal neural functions

Inventive Principle:
Principle #25Self-service

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The formulation rapidly alleviates pain, swelling, inflammation, and restores range of motion in over 90% of clinical subjects with refractory pain and frozen muscles, demonstrating partial or complete cessation of persistent pain and normalization of neural function without blocking normal pain transmission or causing adverse effects.

Implementation Method 1

stimulates lymphatic flow and clearance, disrupting cytokine-induced neural malcircuitry by removing accumulated neurotransmitters and cytokines

Methodology Applied
Scientific EffectLymphatic flow:

Data Source

PatentUS8658227B2Botanical formulation derived from birch bark
Publication Date: 2014.02.25 RADENTZ LESLIE MARIE

AI summary

A formulation and method of mitigation of symptoms of patients suffering from a neurocutaneous pain syndrome by topical application of the formulation. The formulation is obtained by steeping the bark of a tree from the genus Betula in an aqueous acidified solution and then subsequent filtering, packaging and sterilization.